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AIDS AS A CHRONIC ILLNESS: A CAUTIONARY TALE 
FOR THE END OF THE TWENTIETH CENTURY 
Linda C. Fentiman* 
Forecasting is always a risky business, particularly a t  the begin- 
ning of the year. Nonetheless I predict that 1998 will be the year 
that AIDS becomes a mainstream disease, no more likely to receive 
special legal solicitude or extra government funding than other 
chronic diseases which afflict a wide spectrum of American society. 
AIDS is ready to come of age and lose its status as a specialty dis- 
ease, due to the confluence of four major phenomena. These are: 
(1) significant clinical innovations in AIDS treatment,l(2) a shift in 
the demographics of persons living with AIDS and HIV,2 (3) a re- 
configured and refinanced health care delivery system,3 and (4) new 
legal thinking about people with disabilities.4 Some AIDS advo- 
* Professor of Law and Director, Health Law and Policy Program, Pace University School 
of Law. B.S., Cornell University, 1970; J.D., State University of New York at  Buffalo Law 
School, 1975; LL.M., Harvard University School of Law, 1983. The author gratefully ac- 
knowledges the advice and counsel of Professor Joshua Greenberg and the invaluable re- 
search assistance of Marleen Kelley, Pace University School of Law, Class of 1999. 
1 See Deborah Sontag & Lynda Richardson, Doctors Withhold H.I.V. Pill Regimen fiom 
Some, N.Y. TIMES, Mar. 2, 1997, at A1 (discussing protease inhibitors as an AIDS treatment 
that will prolong patients' lives). 
a See David Brown, Poverty Entangles Promise of Powerful Treatment, WASH. POST, Sept. 
1,1997, at  A1 (reporting an increase in the number of African-Americans, women, and intra- 
venous drug users living with HIV and AIDS rather than gay white men who made up a 
majority of the AIDS sufferers in the 1980s); Minorities Miss Out on AlDS Survival Increase, 
AIDS ALERT, May 1, 1997, available in 1997 WL 8961938 (noting that African-Americans 
have AIDS at seven times the rate of whites, and Hispanics have AIDS at  three times the 
white rate). 
3 See RAND E. ROSENBLA~ ET AL., LAW AND THE AMERICAN HEALTH CARE SYSTEM 12 
(1997); Eleanor D. Kinney, Medicare Managed Care from the Beneficiary's Perspective, 26 
SETON HALL L. REV. 1163, 1163 (1996) (stating that "managed care is fast becoming the pre- 
dominant model for the delivery of health care services in the United States"); see also Her- 
bert M. Dean, As I See it, TELEGRAM & GAZETIX (Worcester, Mass.), Sept. 29, 1997, at  A7 
(discussing the high rates of growth in Health Maintenance Organization [hereinafter HMO] 
programs and managed care). 
4 See Arti Kaur Rai, Rationing Through Choice: A New Approach to Cost-Effectiveness 
Analysis in Health Care, 72 IND. L.J. 1015, 1016-19 (1997) (arguing for cost-effectiveness in 
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cates themselves are beginning to reassess the desirability of "AIDS 
exceptionalism," the notion that because the diagnosis of HIV is 
both clinically devastating and socially stigmatizing, HIV and AIDS 
require special status and special resources.6 In addition, public 
health specialists and some AIDS advocacy groups, including the 
Gay Men's Health Crisis in New York, support the idea of manda- 
tory reporting of HIV test results to state health departments.6 
Mandatory reporting permits the collection of more accurate epi- 
demiological data on the incidence of HIV infection, as well as 
AIDS, now that HIV infection itself is recognized as a chronic 
health condition necessitating medical intervention.7 This new 
openness to data collection reflects a growing consensus that HIV 
and AIDS are less stigmatizing than they once were, as more and 
more Americans' lives are touched by the disease. At the same 
time, the urgent need for more accurate information for formulating 
public health policy is seen by some to outweigh the infringement of 
individual privacy rights and the potential deterrent effect on those 
seeking HIV and AIDS treatment that have traditionally been 
grounds for opposing mandatory HIV reporting, particularly if 
names are attached to positive test results.8 
In examining the demise of AIDS as sui generis, it is necessary to 
understand the impact of converging medical, financial, and socio- 
political forces over the last fifteen years. During that time AIDS 
has evolved from a swiftly fatal illness whose etiology was un- 
known, to a well-studied, treatable chronic disease where death can 
frequently be staved off for a lengthy time, although not forestalled 
altogether.9 AIDS is thus similar to many other chronic diseases 
rationing health care); Chris Watkins, Comment, Beyond Status: The Americans with Dis- 
abilities Act and the Parental Rights of People Labeled Developmentally Disabled or Mentally 
Retarded, 83 CAL. L. REV. 1415, 1430 (1995) (noting that one aim of the Americans with Dis- 
abilities Act [hereinafter ADA] is to change legal thinking about people with disabilities). 
6 See Sheryl Gay Stolberg, New Challenge to Idea that "AIDS is Special," N.Y. TIMES, Nov. 
12,1997, at  A1 (emphasizing that AIDS is a special disease that requires a special response). 
6 See, e.g., Michael Lasalandra, Health Offiials May Require Doctors To Report All HW 
Patients in State, BOSTON HERALD, Jan. 14,1998, at 15. 
7 See Lynda Richardson, AIDS Group Urges New York To Start Reporting of H.Z.V., N.Y. 
TIMES, Jan. 13, 1998, at  A1 (noting the importance of states requiring doctors to report AIDS 
cases to public officials). 
8 See First-ever AIDS Incidence Decline Marks Start of a New Era in Epidemic, AIDS 
ALERT, Nov. 1, 1997, available in 1997 WL 8961981 (stating that improving the ability to 
monitor HIV infection is essential to determine patterns of the AIDS epidemic and to finding 
cures). 
9 See Deborah J. Cotton, Improving Survival in Acquired Immunodeficiency Syndrome: Is 
Experience Everything?, 261 JAMA 3016, 3016 (1989) (discussing the progress in treatment 
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for which a remarkable series of genetic, medical, and pharmaceuti- 
cal advances now hold out the potential for control, if not cure.10 
With AIDS, substantial treatment breakthroughs have occurred 
in the year and a half since the 1996 International Conference on 
AIDS in Vancouver.11 Thousands of HIV-positive and AIDS pa- 
tients across the United States have embarked upon new treatment 
regimens, taking protease inhibitors daily along with other drugs.12 
In many cases, these individuals have experienced significant re- 
mission in their disease.13 These new "cocktails" are so successful 
for many people that in 1996, for the first time since the AIDS epi- 
demic began, the number of deaths nationwide due to AIDS fell 
compared to the year before.14 The trend has continued in 1997, 
with data from New York City showing that the death toll from 
AIDS decreased by forty-eight percent.15 
Dramatic clinical breakthroughs have also changed the standard 
of care and quality of life for other chronic disease sufferers. The 
nicotine patch has helped smokers withdraw from their tobacco ad- 
diction, thus halting the onslaught of emphysema, cancer, and car- 
diovascular disease.16 Psychotropic drugs have shortened hospital 
for AIDS). Advances in AIDS treatment helps persons primarily in the Western developed 
world who have access to expensive, innovative treatment, and who are lucky enough to re- 
spond well to it. This Article limits its observations to the United States. 
10 See David Brown, "Triple Therapy" Doesn't Destroy H N ,  WASH. POST, Nov. 14, 1997, at  
A4 (noting that while progress is slow, and final results are speculative, new drug break- 
throughs can help to control HIV infection). 
11 See AIDS Deaths Fall Sharply; New Treatments Credited, WASH. POST, Feb. 3, 1998, at  
A2 (attributing the decline in AIDS deaths in 1997 to treatment breakthroughs); David 
Brown, With Fanfare, Global AIDS Conference Gets Underway in Vancouver, WASH. POST, 
July 8, 1996, a t  A4 (reporting the opening of the eleventh International Conference on AIDS). 
12 Protease inhibitors work by interfering with the HIV virus's ability to copy itself, thus 
limiting its spread within the body. See Thomas H. Maugh 11, Hopes Rise for Inexpensive 
AIDS Drug, L.A. TIMES, Feb. 6,1998, at  Al. 
13 See Lawrence K. Altman, AIDS Deaths Drop 48% in New York, N.Y. TIMES, Feb. 3, 
1998, at A1 (analyzing data to show the progress of new AIDS treatments). 
14 See Centers for Disease Control and Prevention, Update: Trends in AIDS Zncidence- 
United States, 1996,46 MORBIDITY & MORTALITY WKLY. REP. 861,861 (1996) (noting the de- 
cline in AIDS deaths in 1996). 
16 See Altman, supra note 13, at Al. 
16 See Matthew Baldini, The Cigarette Battle: Anti-Smoking Proponents Go for the Knock- 
out, 26 SETON HALL . REV. 348,370 (1995) (stating that lung cancer was the most prevalent 
cancer linked to smoking, and noting other smoking related diseases such as chronic bronchi- 
tis, emphysema, and coronary artery disease); J. Michael McGinnis & William H. Foege, Ac- 
tual Causes of Death in the United States, 270 JAMA 2207, 2208-10 (1993) (finding that to- 
bacco ranks as one of the leading causes of death among Americans); Christina Del Valle, 
Want to Stop Smoking? There Are More Ways than Ever To Quit, NEWSDAY, Jan. 19, 1998, at  
B13 (observing the availability of nicotine patches, gums, sprays, and inhalers to help smok- 
ers quit). 
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stays and liberated many mentally ill people from debilitating de- 
pression, schizophrenia, and bipolar disorders.l7 Similarly, pancre- 
atic transplants (including the Islets of Langerhans, the source of 
insulin) are poised to radically alter the treatment of diabetes.ls 
During this same time period the landscape of American health 
care has changed dramatically. In the early 1980s, health care in 
the United States was largely provided within a fee-for-service sys- 
tem, in which eighty percent of Americans under age sixty-five had 
private health insurance, primarily through employment, with rela- 
tively comprehensive coverage.19 Today, managed care is the pre- 
dominant form of health care delivery in the United States.20 Man- 
aged care relies on new organizational delivery structures, both 
corporate and contractual, utilization review processes, and finan- 
cial incentives to provide less care, in order to contain costs and to 
avoid medically unnecessary and potentially dangerous treatment.21 
At the same time, slightly more than half of all Americans receive 
health care coverage through an employer who is self-insured.22 
Because of the Employee Retirement Income Security Act of 197423 
(ERISA) preemption by these employee benefit health plans are not 
17 See Lou Chapman, Fear of Mentally Ill Called Sign of Ignorance, FORT WORTH STAR- 
TELEGRAM, Apr. 11, 1997, at 2 (stating that drugs reduce the need for hospitalization and 
counseling, and that 60% to 80% of  bipolar disorders can be treated with drugs); Deborah 
Kelly, Medicating the Mind: Breakthrough Drugs May Hold Promise for Many, RICHMOND 
TIMES-DISPATCH, Dec. 11, 1997, at E l  (stating that new antipsychotic medications have been 
called miracle drugs for persons with schizophrenia and manic-depression). 
18 See Kathleen Doheny, Body Watch Zeroing in on Diabetes, L.A. TIMES, May 28, 1997, at 
E2 (discussing one transplantee's foray into pancreas transplantation); David N. Leff, French 
Diabetologists Couple Cholera Toxin to Insulin as Diabetes Type 1 Vaccine, BIOWORLD TODAY, 
May 6 ,  1997, available in 1997 W L  7473764 (stating that pancreas transplants can be a suc- 
cessful cure for diabetes); John G. Leyden, A Good Idea and a Lot of Sweat Led to Diabetes 
Treatment; Insulin Developed by Team Effort Without Team Spirit, WASH. POST, Apr. 22, 
1997, at Z18 (discussing the discovery of  the Islets of  Langerhans, the small microscopic cell 
clusters which produce insulin). 
19 See ROSENBLA~T ET AL., supra note 3,  at 12 (discussing the structure of  the health care 
delivery system). 
20 See Kinney, supra note 3,  at 1163 (stating that both public and private payers are 
seeking to control the escalating costs o f  health care); see also Dean, supra note 3,  at A7 
(noting that over 70% of  employer sponsored health care is in  some form of managed care). 
21 See Diana Joseph Bearden & Bryan J. Maedgen, Emerging Theories of  Liability in the 
Managed Health Care Industry, 47 BAYLOR L. REV. 285, 288-89 (1995) (discussing the meth- 
ods managed care organizations use to evaluate patient care); Elaine Lu, The Potential Effect 
of Managed Competition in Health Care on Provider Liability and Patient Autonomy, 30 
HARV. J. ON LEGIS. 519,521-28 (1993) (same). 
22 See Alex Pham, Aetna To Halt Some Infertility Coverage: Thousands To Be mec ted  in 
Mass., BOSTON GLOBE, Jan. 10, 1998, at F1 ("Approximately half o f  the nation's insured 
population belong to self-insured plans, according to insurance experts."). 
23 29 U.S.C. $3 1001-1461 (1994). 
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governed by state laws providing relief when insurance coverage is 
"unfairly" denied,24 thus leaving many employees and their families 
remediless when a plan will not cover arguable medically necessary 
care. 
Federal efforts to protect people from the most Draconian aspects 
of health insurance have met with limited success, and are largely 
incremental in nature. They include the Health Insurance Port- 
ability and Accountability Act of 1996 (HIPAA),25 which was de- 
signed to limit the impact of preexisting conditions on access to in- 
surance, and the Mental Health Parity Act of 1996,26 .which 
requires that when employee benefit plans offer coverage for both 
physical and mental illnesses, the total dollar value of the coverage 
must be the same, unless the employer demonstrates financial 
hardship.27 There are millions of Americans who are either forced 
to stay in a job they don't want solely because of its health insur- 
ance coverage or who lack access to needed medical services be- 
cause they happen to have the wrong disease. Nearly forty-two 
million Americans lack any health care insurance, even the gov- 
ernment financed insurances of Medicare and Medicaid.28 In New 
York City, twenty percent of the population under age 65 is unin- 
sured.29 
The result of these monumental shifts in the structure and fi- 
nancing of health care delivery is that a t  the very time that medical 
innovations have made possible significant improvements in the 
quality and quantity of life for people with chronic illnesses, those 
who are responsible for paying for Americans' health care, in gov- 
ernment and the private sector, seem to have finally said "Enough! 
We must cut costs, and cut them dramatically, and the simplest, 
most direct way of cutting costs is to deny coverage for certain 
kinds of treatments and certain kinds of illnesses." People with HIV 
and AIDS are among those who are struggling, often unsuccess- 
fully, for access to medically necessary treatment, but they are no 
24 See Michael T. Isbell, AIDS and Access to Care: Lessons for Health Care Reformers, 3 
CORNELL J.L. & PUB. POL'Y 7,21(1993). 
26 Pub. L. No. 104-191,110 Stat. 1936 (1996). 
26 42 U.S.C. 8 3OOgg-5 (1994). 
27 See id. 
28 See PAUL ~ N S T I N ,  SOURCES OF HEALTH INSURANCE AND CHARACTERISTICS OF THE 
UNINSURED 2 (Employee Benefit Research Institute Issue Brief No. 192, 1997) 
(demonstrating that 41.4 million non-elderly Americans have no health care insurance). 
29 See Ian Fisher, Even as Economy Booms, More People Are Going Without Insurance, 
N.Y. TIMES, Feb. 12, 1998, at B1 (noting that the number of people without medical insur- 
ance is rising far faster in New York State than in the rest of the country). 
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longer alone. Millions of other Americans living with chronic dis- 
ease face similar problems as they seek medical treatment that is 
effective, multi-faceted, and expensive in a health care system in- 
creasingly bent on controlling both the costs the structures of 
health care delivery. We thus stand at  the threshold of a critical 
question: What lessons does the AIDS pandemic provide for Ameri- 
can health care in general? 
It is always cheaper to prevent illness than to treat it.30 AIDS, 
along with many other illnesses linked to human behavior, exempli- 
fies the limitations of American public health policy as it is directed 
at  chronic disease reduction. Government and private payers spend 
very little on cost-effective preventive public health strategies.31 
State health departments spend only three percent of their budgets 
on prevention and less than one percent of government funding 
supports public health initiatives.32 Although approximately $425 
billion was spent in 1994 to treat the six major chronic diseases 
(heart disease, cancer, stroke, diabetes, chronic obstructive pulmo- 
nary disease, and chronic liver disease), less than one percent of 
30 See Stephenie Overman, Managed Care Companies Still Emphasize Prevention, L.A. 
BUS. J. ,  Sept. 22, 1997, available in 1997 WL 9559235 (noting that some HMOs are starting 
to place more emphasis on prevention); Thomas J. Prohaska, Health Leader Backs Needle 
Exhange, BUFF. NEWS, Sept. 28, 1997, a t  C1 (arguing that focusing on the prevention of 
HIV/AIDS is cost effective). 
31 Indeed, the publicity which has attended the successful clinical and pharmaceutical in- 
novations in AIDS treatment in the United States and other Western countries has obscured 
the growing AIDS pandemic in the rest of the world, where drug therapies are far too expen- 
sive to be useful to more than a handful of those infected with HIV. Western AIDS research 
efforts, both publicly and privately funded, have concentrated on treatment breakthroughs, 
while for other countries, the only hope for limiting the spread of the disease is in prevention, 
through education about high risk behaviors, and the development and use of an  AIDS vac- 
cine. See Andrew Purvis, The Global Epidemic, TIME, Dec. 30, 1996, a t  76-78 (describing re- 
cent AIDS prevention programs in African countries). In the United States Phase I11 clinical 
trials are about to begin for an  AIDS virus drug. See AIDS Vaccine Approved for Human 
Trials, WASH. POST, Jan. 12, 1998, a t  All (reporting that the first AIDS vaccine has been 
approved by the Food and Drug Administration to move to "phase I11 testing"). A recent 
United Nations report estimated that there are 16,000 new cases of HIV infection each day. 
See Robert Pear, New U.N. Estimate Doubles Rate of Spread of AIDS Virus, N.Y. TIMES, Nov. 
26,1997, a t  A3. 
32. See Medical Costs To Surge for Chronic Disease Treatment, MED. INDUS. TODAY, Apr. 7, 
1997, available in LEXIS, News Library, Medtdy File; see also Edward L. Baker e t  al., Health 
Reform and  the Health of the Public: Forging Community Health Partnerships, 272 JAMA 
1276, 1277 (1994) (stating there has been an  "erosion of core public health finding). 
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that amount ($287 million) was spent on prevention efforts.33 Many 
health care insurers and other payers do not pay for preventive 
health care (well-baby check-ups, mammographies, etc.), although 
this may change as managed care, which has marketed preventive 
care as one of its hallmarks, gains greater prevalence in American 
health care delivery.34 In 1993, Drs. Michael McGinnis and William 
Foege estimated that approximately one half of all deaths in the 
United States could be forestalled by prophylactic health care 
measures, including changes in sexual and driving behavior, food 
and alcohol consumption, and the use of tobacco and other drugs.35 
For example, we know that more than forty percent of high school 
students, both boys and girls, use cigarettes and other tobacco 
products, and that eighty-five percent of current adult smokers be- 
gan before the age of 18.36 In forty years, many of these students 
will become sufferers from cancer, emphysema, and heart disease. 
Similarly, McGinnis and Foege suggested that as many as 300,000 
deaths annually could be prevented if people decreased their con- 
sumption of calories, particularly animal fat, and increased their 
level of exercise, thus reducing their risk of developing diabetes and 
heart disease.37 
With AIDS, four effective prevention strategies have been identi- 
fied: counseling individuals to change their sexual and other high 
risk behaviors, explicit sex education programs, condom distribu- 
tion, and the provision of clean needles to intravenous drug users.38 
Public and private health policymakers have frequently resisted the 
implementation of these strategies for moral, fiscal, or political rea- 
33 See Medical Costs To Surge for Chronic Disease Treatment, supra note 32. 
34 See A Managed Care Primer, PEOPLE'S MED. SOC'Y, Oct. 1,1997, at A1 (noting the goals 
o f  managed care are to provide services to keep people healthy); David Algeo, Managing 
Medicaid HMO's New Law Presents Challenges for Health-Maintenance Organizations, 
DENVER POST, June 29,1997, at H1 (stating managed care focuses on prevention of illness). 
36 See McGinnis & Foege, supra note 16, at 2211 (linking approximately half o f  all deaths 
in the United States to identifiable factors). 
36 See Sheryl Gay Stolberg, Rise in  Smoking by Young Blacks Erodes a Success Story, 
N.Y. TIMES,  Apr. 3,  1998, at A24; Professor Richard J. Bonnie, Presentation at the Pace Uni- 
versity School o f  Law Conference, Tobacco and the Public Health: Social Policy and Legal 
Issues (Apr. 19, 1997). 
37 See McGinnis & Foege, supra note 16, at 2208 (estimating that 35% of  all cancer deaths 
are attributable to  diet). 
38 See William N. Eskridge, Jr. & Brian D. Weimer, The Economics Epidemic in  an  AIDS 
Perspective, 61 U .  CHI. L. REV. 733, 766-70 (1994); Needle Exchange Programs Comprehen- 
. sive Approach Found To Be Best Way To Prevent HIVAmong Drug Users, AIDS WKLY. PLUS, 
Sept. 22,1997, at 19, available in 1997 WL 11007268. 
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sons.39 Similar short-sightedness characterizes most states' regula- 
tion of hypodermic syringes, as they severely limit access to sy- 
ringes in order to discourage drug abuse, overlooking the increased 
transmission of hepatitis, HIV, and other blood-borne diseases 
which inevitably accompanies such restrictive measures.@ 
Numerous studies demonstrate that an ongoing relationship with 
a health care professional is crucial to changing a person's sexual 
behavior by influencing the individual to use condoms or to limit 
the number of sexual encounters, but this knowledge has not been 
effectively implemented due to organizational or political con- 
straints on health care delivery.41 Although many managed care 
organizations endeavor to ensure continuity of care, frequently 
their patients do not see the same health care provider regularly, 
and thus lack the sort of practitioner-patient relationship which can 
encourage a change in high risk behavi0r.4~ As governments reduce 
access to sexually transmitted disease clinics and other reproduc- 
tive healthcare services, they lose a valuable opportunity to counsel 
people about the risks of unprotected sex and intravenous drug 
use.43 Unprotected sexual intercourse accounted for more than 
30,000 deaths in 1990, including 21,000 from sexually acquired HlV 
infections, 4000 from cervical cancer, 1600 from sexually acquired 
Hepatitis B infections, and 5000 deaths of infants due to unplanned 
pregnancies and a concomitant lack of prenatal care.44 In almost all 
states possession of a hypodermic needle or syringe with the intent 
to use it to inject drugs is illega1.45 Eight states additionally require 
a prescription to purchase a needle or syringe, although several of 
the states, including New York, permit syringe possession in con- 
3g See Lawrence 0. Gostin et al., Prevention of HNIAIDS and Other Blood-Borne Dis- 
eases Among Injection Drug Users: A National Survey on the Regulation of Syringes and 
Needles, 277 JAMA 53,54-55 (1997). 
40 See id. at 54 (noting "[dlrug paraphernalia statutes ban the manufacture, sale distribu- 
tion, possession, or advertising.. . of devices known to be used (or reasonably should be 
known to be used) to introduce illicit substances into the body"). 
41 See, e.g., James G. Kahn, The Cost-Effectiveness of H N  Prevention Targeting: How 
Much More Bang for the Buck?, 86 AM. J. PUB. HEALTH 1709, 1711 (1996) (suggesting that 
HIV prevention services help to stop the spread of HIV and reduce costs). 
42 See Isbell, supra note 24, at 27-28. 
43 See Jim Yardley, Breaking the H.Z.V. Chain: Clinic Battles Spread of Infection-nd 
Despair, N.Y. TIMES, Jan. 25, 1998, at  K27. 
44 See McGinnis & Foege, supra note 16, at  2210. 
45 See Gostin et al., supra note 39, at  54 ("Forty-seven states, the District of Columbia, 
and the Virgin Islands have enacted drug paraphernalia laws; only Alaska, Iowa, South 
Carolina, and four territories have no state-or territory-wide drug paraphernalia stat- 
ute."). 
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nection with a state-approved syringe exchange program.46 These 
programs have been shown to cut the rates of H N  infection sub- 
stantially.47 
Aggressive interventions to reduce the incidence of other chronic 
diseases have been proposed, including the Food and Drug Admin- 
istration's (FDA) regulations banning most advertising of tobacco 
products to children under eighteen,* and screening of high risk 
groups for diabetes.49 Other preventive public health measures, 
which have not generally been implemented with AIDS, but have 
been used historically with other diseases, include isolation and 
quarantine.50 Some communities have invoked the public health 
police power to limit the opportunities for high risk activities by 
prohibiting the use of closed video booths in adult bookstores and 
entertainment centers,61 and closing bathhouses and other locations 
where there are opportunities for high risk sexual activity.62 More 
recently, the question of whether there should be mandatory con- 
tact tracing andlor reporting of persons who test HIV positive has 
been hotly debated in the wake of highly publicized allegations that 
46 See id. at  56. 
47 See Felicia R. Lee, Needle Exchange Programs Shown To Slow H.Z.V. Rates, N.Y. 
~IMEs, Nov. 26, 1994, at  A4 (noting that intravenous drug users who are not involved in a 
needle exchange program have a two percent to five percent higher rate of HIV infection 
than those in a needle exchange program). 
48 See Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless To- 
bacco to Protect Children and Adolescents, 21 C.F.R. 8 897.2 (1996) (noting the purpose of 
the regulation is to prohibit the sale of nicotine cigarettes and smokeless tobacco products to 
children). 
49 See Geraldine A. Collier, Battling Diabetes, the Silent Killer, TELEGRAM & GAZETTE 
(Worcester, Mass.), Jan. 20, 1997, at C l  (discussing the need for intensive intervention 
andlor medication to decrease the risk of diabetes); Kamilla Kuroda McClelland, New Base- 
line Formed for Diabetes: High-Risk; Nikkei Are More at  Risk than Japanese in Japan, N. 
AM. POST, June 27, 1997, at  1 (encouraging Japanese-Americans to be screened earlier and 
more often to catch and treat the disease earlier). 
60 See Jew Ho v. Williamson, 103 F. 10,26 (N.D. Cal. 1900) (noting the quarantine of San 
Francisco's Chinatown, because of an ostensible outbreak of bubonic plague, was invalid un- 
der the Fourteenth Amendment); Kirk v. Wyman, 65 S.E. 387, 388 (S.C. 1909) (upholding a 
lower court's grant of a preliminary injunction to restrain the removal of a woman with lep- 
rosy to the city "pesthousen because of the asserted contagious nature of her disease). Cuba 
is the only nation to seriously attempt isolation of all HIV-positive patients achieving a very 
low rate of HlV infection, but Cuba abandoned its isolation program due to its high costs. 
See Juanita Darling, New Day for AIDS Policy in Cuba, L.A. TIMES, July 24, 1997, at  B2 
(discussing the Cuban government's approach to AIDS infected people). 
61 See Doe v. Minneapolis, 898 F.2d 612 (8th Cir. 1990). 
See New York v. New St. Mark's Baths, 497 N.Y.S.2d 979 (Sup. Ct.), afd, 505 N.Y.S.2d 
1015 (App. Div. 1986). 
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a young man from New York City has been the source of a one man 
AIDS epidemic in Jarnestown, a small town in upstate New York.53 
11. LESSON #2: AIDS AS A CHRONIC ILLNESS AND ACCESS TO 
HEALTH CARE 
The most salient feature of the evolution of AIDS over the past 
decade and a half is that it has become a chronic illness. Today, 
cases involving HIV-positive individuals and persons with AIDS are 
paradigms for the problems that many people with chronic diseases 
face in receiving care. The issues of access arise in a variety of con- 
texts, including the ability to secure primary health care, to receive 
emergency medical treatment, to obtain quality specialist care, and 
to receive innovative, and often expensive treatment. 
A. Access to Primary Care 
People who are HIV positive or who have AIDS, or are suffering 
from diabetes, lupus, or hepatitis B, require primary medical and 
dental care in addition to specialty healthcare. Frequently those 
who have the HIV or AIDS disease find it difficult to find a provider 
who will treat them. In Abbott v. Bragdon,54 an asymptomatic HIV- 
positive woman who sought routine dental treatment to fill a cavity 
disclosed that she was HIV positive.55 The dentist, Dr. Bragdon, re- 
fused to treat her, except in a hospital setting, where the cost of 
treatment would be greater.56 After declining this offer, Ms. Abbott 
brought suit under the Americans with Disabilities Act of 199057 
(ADA). The First Circuit Court of Appeals held that Ms. Abbott 
was disabled within the meaning of the ADA because she was a 
person with asymptomatic HIV who was limited in a major life ac- 
tivity, i.e., reproduction.58 The court held that the burden was 
therefore shifted to Dr. Bragdon to show that he was not obligated 
63 See Jane Gross, Trail of Arrests, H.Z.V. Fears and a Woman's Tale of love, N.Y. TIMES, 
Oct. 29, 1997, at Al; Tom Precious, HN Proposals Call for Testing, Disclosure, BUFF. NEWS, 
Dec. 18, 1997, at A16. 
54 107 F.3d 934 (1st Cir.), cert. granted, 118 S. Ct. 554 (1997). 
56 See id. 
66 See id. at 937. 
57 42 U.S.C. 5 12101 (1994). 
68 See Abbott, 107 F.3d at 939, 941. A plaintiff suing under the ADA is required to prove 
three things: (1) that the plaintiff has a physical or mental impairment; (2) that such im- 
pairment adversely affects a "major life activity"; and (3) that the limitation is significant. 
See id. at 938-39. 
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to treat her because she posed a direct threat to his health and 
safety.59 Abbott marked the first time that a court held that asymp- 
tomatic HIV status alone was sufficient to qualify as a disability 
under the ADA, and was also important in recognizing that physi- 
cians and dentists offices are places of public accommodation within 
the protection of the ADA.60 
Other commentators, including Professor Scott Burris, have 
noted the significant difficulties that HIV-positive individuals and 
persons with AIDS have in gaining access to routine dental care.61 
Similar difficulties in obtaining routine primary care are faced by 
persons with hearing impairments, blind persons who rely upon 
guide dogs for assistance in gaining access to a physician's office, 
and those whose mental impairments make them unpopular pa- 
tients with primary care providers. G2 
B. Access to Emergency Care 
Individuals who are HIV positive or who suffer from AIDS have 
often found it difficult to receive emergency medical care because of 
the concern of hospitals and physicians, whether or not well- 
founded, that the patient's illness is too complex to be readily 
treated in an emergency room and that an AIDS patient, once ad- 
mitted, may prove to be a costly admission.63 The practice of re- 
fusing admission to an uninsured or otherwise undesirable patient 
59 See id. at  948 (finding the evidence offered to buttress his claim was "too speculative or 
too tangential"). 
60 See id. at 939 (stating that both symptomatic and asymptomatic HIV-positive persons 
are covered by the Act). The Supreme Court has granted certiorari in Abbott. See 118 S. Ct. 
554 (1997). A decision in Abbott will likely have an impact on another key decision involving 
an HIV-positive employee who was terminated. See Runnebaum v. Nationsbank of Md., 123 
F.3d 156 (4th Cir. 1997). It is noteworthy, however, that Runnebaum arose in the context of 
employment discrimination and the court found no evidence that the plaintiffs HIV positive 
status limited him in his procreative functions, thereby offering a possible distinction from 
Abbott. See id. at 169-70. 
61 See Scott Burris, Dental Discrimination Against the HN-Infected: Empirical Data, Law 
and Public Policy, 13 YALE J .  ON REG. 1, 4 (1996) (analyzing empirical studies on dentists' 
attitudes toward patients with HIV and concluding that many dentists are uncomfortable 
treating such patients). 
6~ See Tugg v. Towey, 864 F. Supp. 1201, 1211 (S.D. Fla. 1994) (granting a preliminary 
injunction under the ADA to deaf and hearing-impaired plaintiffs seeking mental health 
counseling from therapists who used sign language, rather than relying on sign language 
interpreters); Mayberry v. Von Valtier, 843 F. Supp. 1160 (E.D. Mich. 1994) (involving a deaf 
patient whose physician no longer wanted to pay for an interpreter to be present during ap- 
pointments). 
63 See Howe v. Hull, 874 F. Supp. 779, 783 (N.D. Ohio 1991) (claiming that a patient was 
transferred to another hospital because of his HIV status). 
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is known colloquially as "patient dumping."64 It has been addressed 
by some state courts which have found a common law duty to 
treat,66 and, on the federal level, by the Emergency Medical Treat- 
ment and Active Labor Act66 (EMTALA), which requires that all pa- 
tients who arrive at  a hospital emergency room shall receive an ap- 
propriate medical screening examination to determine if they are in 
the midst of a medical emergency or active labor, and prohibits 
their transfer in a medically unstable condition, unless the physi- 
cian certifies in writing that the benefits of the transfer outweigh 
its potential risks.67 The exemplary AIDS case is Howe v. Hu11.68 
Fred Charon, a patient with AIDS, sought treatment a t  the emer- 
gency room of a community hospital when he suffered a severe pre- 
scription drug reaction unrelated to his underlying AIDS condi- 
tion.69 Charon was denied admission to the hospital and 
transferred to a nearby academic medical center.70 Although the 
transfer was ostensibly due to the treating physician's concern that 
Charon was suffering from a complicated drug reaction, requiring 
treatment at  the academic medical center, ample evidence sug- 
gested that the drug reaction was simple and readily treatable at 
the community hospital, and that the transfer was motivated by 
Charon's AIDS status.71 A suit followed, asserting claims under 
state tort law for the infliction of emotional distress, the ADA, the 
Federal Rehabilitation Act of 197372 and EMTALA. The defendant- 
physician and hospital were found liable for intentional infliction of 
emotional distress, and violating the ADA and the Rehabilitation 
Act, but the claims under EMTALA were rejected.73 Still, as an al- 
legedly "dumped7' patient, Charon symbolizes the growing number 
of Americans with socially disfavored chronic diseases who have dif- 
ficulty gaining access to vitally necessary hospital emergency care. 
a See id. at 784. 
6s See Thompson v. Sun City Community Hosp., Inc., 688 P.2d 605 (Ariz. 1984) (involving 
a hospitals transfer of an unstable patient to another hospital for surgery); Wilmington Gen. 
Hosp, v. Manlove, 174 A.2d 135 (Del. 1961) (involving a hospital transfer of an infant in a 
potentially emergent situation, who later died due to a lack of care). 
66 42 U.S.C. J 1395dd (1994). 
67 See id. J 1395dd(c)(l)(A)(i)-(iii). 
66 874 F. Supp. 779 (N.D. Ohio 1994). 
69 See id. at 783. 
70 See id. at 783-84. 
71 See id. at 786. 
72 29 U.S.C. J 701 (1994). 
73 See Howe, 874 F. Supp. at 791. 
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C. Access to Specialty Care 
HIV-positive individuals and AIDS patients exemplify the prob- 
lems of many sufferers from chronic diseases who need specialized 
medical care, but have difficulty in gaining access to it due to the 
limited knowledge of their primary care providers. In some cases, 
the primary care provider is not sufficiently knowledgeable to rec- 
ognize the disease and provide the necessary care. People with 
Sjogrens Syndrome, a disease of the autoimmune system that 
causes a loss in moisture functions in the tear ducts and the sali- 
vary glands, leading to vision and oral hygiene problems, are often 
undiagnosed because of a lack of awareness in the general medical 
and dental communities.74 In other cases, the primary care pro- 
vider lacks the knowledge to make an appropriate referral. This 
was a common experience among HIV-positive and AIDS patients, 
particularly in the early stages of the AIDS epidemic. At that time, 
many physicians and AIDS activists believed that people living 
with HIV and AIDS were not receiving sufficient referrals to spe- 
cialists and subspecialists, which were desperately necessary be- 
cause generalist physicians were frequently unqualified to deliver 
care.75 
A different concern in the debate about access to specialty care is 
that patients suffering from a particular disease, such as AIDS, 
may become isolated in special treatment units as the pariahs of 
the patient community. Today, this discussion about the 
"ghettoization" of AIDS plays itself out in the controversy sur- 
rounding New York State Health Department regulations man- 
dating HIV testing for all newborns, which require that infants and 
their mothers diagnosed as HIV positive be referred to AIDS spe- 
ciali~ts.~6 Opponents of the regulations argue 'that all primary 
health providers should be able to provide appropriate care for 
AIDS patients, and that mandating specialty referrals may lead 
again to the medical and social isolation of HIV-positive individuals 
- 
74 See Joyce Howard Price, Ailment Keeps Millions in Misery: Sjogren's Syndrome Goes 
Undiagnosed for Most Sufferers, WASH. POST, Dec. 28,1997, at A2. 
75 See New York City HMOs Not Ready To Serve HW-Positive Women, Children, Study 
Says, Health Care Daily (BNA) (Oct. 13, 1995), available in LEXIS, BNA Library, Bnahlt 
File. 
76 See N.Y. COMP. CODES R. & REGS. tit. 10, 8 69-1.3 (1995) (mandating newborn testing); 
Charles W .  Henderson, Transmission Baby AIDS Testing Law Faces Legal Challenge, AIDS 
WKLY. PLUS, July 28,1997, available in 1997 W L  11006861 (discussing both support and op- 
position to the mandatory newborn testing law). 
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and AIDS patients.77 However, to the extent that there is any con- 
sensus in the HIV-positive and AIDS community, it is that people 
living with AIDS and HIV, as with any chronic disease, need to 
have their health care overseen by a practitioner with sufficient ex- 
pertise to manage a complex treatment regimen, who is able to 
make immediate and competent referrals should the disease prog- 
ress beyond his or her capabilities to treat it. 
For the increasing numbers of Americans with chronic diseases 
who receive their health care through a managed care organization, 
there is an additional concern: that the constraints of the 
"gatekeeper" system, in which all care is "managed" by a primary 
care practitioner, will lead to medically harmful delays in, and de- 
nials of, treatment. Whether the patient is identified as being HIV 
positive, or diagnosed with diabetes or hepatitis, the need is for 
immediate referral to an appropriate specialist, who can initiate ef- 
fective treatment, including the appropriate drug therapy. With 
HIV-positive individuals, as well as sufferers from other chronic 
diseases, the concern is always that a delay in treatment may lead 
to irreversible deterioration in the patient's condition. 
D. Access to Experimental Treatment 
HIV and AIDS are similar to many chronic diseases in which the 
standard of care for medical and drug treatment is rapidly evolving, 
leading to major gaps in access to quality health care. Three big 
picture questions have emerged. First, can the process of experi- 
mentation be expedited, so that definitive results can be obtained 
about the efficacy of a particular innovative treatment? Second, 
how soon is it reasonable to expect success at an academic medical 
center to be translated into a standard of treatment that is avail- 
able to patients across the nation at an affordable price? Third, 
should everyone have access to the new standard of care, regardless 
of the type or amount of health care insurance they have? 
In the early stages of the AIDS epidemic, the controversy over ac- 
cess centered around participation in randomized clinical trials for 
experimental drug treatments.78 The FDA asserted that before a 
drug could be approved and marketed, a new drug must go through 
77 See Henderson, supra note 76. 
78 See, e.g., Testing Testing: Clinical Trials Are an Essential-and Expensive-Part of Drug 
Development, ECONOMIST, Feb. 1,1997, available in 1997 W L  8136413 (noting the process for 
drug development). 
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a lengthy series of animal studies and human studies in order to be 
certain that a drug was both safe and effective for its intended 
use.79 Clinical trial guidelines required all testing to be conducted 
via randomized clinical trials, meaning that one could not receive 
an experimental drug, no matter how promising, without partici- 
pating in a clinical trial, and even then, one would not be guaran- 
teed the drug, since the essential nature of a clinical trial requires 
that some persons be in the control gro~p.~O Aggressive protests by 
"Act Up" and other AIDS activist groups led the FDA to promulgate 
"Fast Track," "Parallel Track," and other expedited access regula- 
tions, which have substantially decreased the time necessary to 
gain FDA approval for new pharmaceutical treatments for all pa- 
tients affected with "immediately life-threatening" or "serious" dis- 
ea~es .8~ Recently enacted legislation codifying the FDA's regulatory 
approaches is expected to shorten the drug and medical device ap- 
proval process even more.82 
Today, there is a significant drug arsenal available to combat 
HIV and AIDS, yet access problems remain. Three protease inhibi- 
tors-saquinavir, ritonavir, and indinavir-have proven successful 
in combination with nucleoside analogues in clinical trials and 
clinical practice in interfering with the HIV virus' ability to repli- 
cate itself.83 Early data show that the use of these "combination 
therapies" can halt the progression from HIV positive status to full- 
blown AIDS,-help prevent the opportunistic infections which ulti- 
mately cause death in AIDS patients, and generally improve the 
quality of life of HIV-positive and AIDS patients.84 Many patients 
79 See id. 
80 See, e.g., Stephen Fried, Cocktail Hour, WASH. POST, May 18, 1997, at W10 (discussing 
the access problems arising from clinical guidelines). 
81 See Sheila R. Shulman & Drusilla S. Raiford, FDA Regulations Provide Broader Access 
to Unapproved Drugs, 30 J .  CLIN. F'HIWUCOLQGY 585, 585 (1990) (noting that the goal o f  
new FDA procedures is to facilitate the availability of new medications, and obtain additional 
data on their safety and efficacy); Lawrence M. Fisher, Hope Near the End of the Pipeline, 
N.Y. TIMES, May 1, 1997, at Dl (discussing the introduction of  new cancer treatments); Gina 
Kolata, Interest Grows in  Licensing Shortcut for 2 AIDS Drugs, N.Y. TIMES, Sept. 25, 1990, at 
C3 (noting the effects o f  AIDS activists in  advancing the licensing process). 
82 See Ronald Rosenberg, Biotech Firms Praise FDA Legislation: Bill Streamlines Drug 
Approval Process, BOSTON GLOBE, Nov. 11, 1997, at D5 (discussing the favorable reception 
given to the more streamlined approval process contained in  the FDA legislation). 
83 See, e.g., Grace Brooke Huffman, Review of Protease Inhibitors for Use in  HN-1  Infec- 
tion, AM. FAM. PHYSICIAN, June 1, 1997, available in 1997 W L  10150889 (analyzing the suc- 
cess o f  the protease inhibitors saquinavir, ritonavir, and indinavir). 
84 See Lawrence 0. Gostin e t  al., National H N  Case Reporting for the United States, 337 
NEW ENG. J .  MED. 1161,1162-63 (1997) (discussing the advances in  HIV treatment). 
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have experienced a substantial decrease in the "viral load" of HIV 
in their bloodstream, a recognized biological marker for the advance 
of HIV disease.85 
However, these potent drugs are not available to everyone. The 
primary barrier is financial. It costs $10,000 to $15,000 annually 
just for the drugs for the combination therapy "cocktail," and many 
HIV-positive and AIDS patients require other drugs as we11.86 Re- 
cent data show that this is money well spent, because increased 
costs for drug therapy are offset by declines in the number of in- 
patient hospital admissions and the length of those stays as well.87 
However, private and government insurers have been reluctant to 
incur the up-front costs of combination therapy treatment, illus- 
trating some of the inherent weaknesses of our multi-payer, frag- 
mented health care system, in which different types of health care 
needs are treated differently.88 
Many insurers and managed care organizations place annual 
caps on each patient's drug expenses, leaving patients with AIDS 
and HIV, as well as sufferers from other chronic diseases, with the 
sole option of paying for their necessary pharmaceuticals out of 
pocket if they want to stay healthy.89 In some managed care or- 
ganizations, only a limited group of drugs is on the approved drug 
formulary. If protease inhibitors and other AIDS treatment drugs 
are not on the formulary, the patient is simply out of luck. 
Because many HIVIAIDS patients lose their health insurance 
when they become sick enough to lose their jobs, eventually many 
patients turn to the government to pay for their health care. More 
85 See id. 
86 See Diane Targovnik, Success of New AIDS Drugs Imperils Tax-Funded Program: 
Pharmaceutical "Cocktail" So Costly that State-Federal Assistance Plan Going Broke, NEWS 
TRJB. (Tacoma, Wash.), Jan. 26, 1997, a t  A5 (noting that the cost of HlV drugs makes them 
out of reach of some persons). 
87 See Joan Stephenson, Paying Now for Costly AIDS Drugs May Save Money Later 
(visited Feb. 8, 1998) <http://www.ama-assn.org/special/hiv/newsline/conferedretrocod- 
js0126,htm> (arguing that the decline in hospitalizations justifies the costs of protease in- 
hibitors). 
88 See Charles W Henderson, Quality of Life: AIDS Patients Living Langer While Money 
Problem Grows, AIDS WKLY. PLUS, July 28, 1997, available in 1997 WL 11006856 (observing 
that hospitals and outpatient AIDS clinics are receiving less reimbursement from private 
insurance companies); How Each State Is Faring with Demand for New IZZV Drugs, AIDS 
Pol'y & L. (BNA) 1, 5 (Oct. 4, 1996) (noting that 22 states are expected to limit access to pro- 
tease inhibitors, due to rising costs). 
8s See, e.g., Managed Care Executives Cite Drug Costs as a Barrier to Profits, MANAGED 
CARE OUTLOOK, Aug. 8, 1997, available in 1997 WL 8469939 (observing that HMOs pursuing 
short term budget goals are having problems with the rising costs of medications). 
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than 100,000 AIDS patients receive a t  least some of their drugs 
through Medicaid.90 Under Title I1 of the Ryan White Care Act,gl 
AIDS Drug Assistance Programs (ADAPs) are established in each 
state to assist indigent patients in paying for necessary drugs.g2 
Under this federal-state partnership, each state seeks approval for 
its own ADAP program, choosing to cover those drugs which it be- 
lieves it can afford.93 This has led to wide variations in each state 
in the number of patients served and the particular drugs available. 
For example, New York State's program, which serves more than 
10,000 patients, is one of the most generous in the nation, which is 
perhaps to be expected given the state's significant AIDS popula- 
tion, and the political clout of AIDS advocacy groups.94 Many other 
states do not provide coverage for protease inhibitors, the most ef- 
fective and expensive of the anti-HlV drugs, underscoring that a 
person's access to effective health care can depend significantly on 
the accident of geography.95 In addition, a significant limitation of 
all ADAP programs, and of Medicaid in general, is that they cover 
only persons who have been diagnosed with AIDS, rather than the 
larger group of those who have tested HW positive, perhaps re- 
flecting a political decision that the AIDSHIV dividing line is an 
appropriate way to apportion scarce government resources.96 
However, this decision is unsound both medically and fiscally. 
Protease inhibitors and other advanced anti-AIDS drugs are a sig- 
nificant breakthrough precisely because they can prevent the ad- 
vance of HlV disease to AIDS, thus providing a cost-effective means 
of limiting the spread of AIDS and the concomitant costs of AIDS 
treatment. Viewing the ADAP program as a separate "pot" of 
90 See Deborah L. Shelton, Rising Hopes-Rising Costs (visited Feb. 8, 1998) 
~http~I~~~.ama-assn.org/speciafiiv/newsinsciaamnews-/amnO916.htm> (stating that 
as many as 50,000 additional HIV-infected patients are likely to seek prescription drugs 
through Medicaid). 
91 See 42 U.S.C. $ 30OfF (1994) (establishing the framework for federal assistance to be 
made available to states to provide services for HIV-positive individuals and their families). 
82 See id. 
93 See id. $ 300-ff-22 (describing how states may use the federal grants). 
94 See David Brown, AIDS Toll Falls by Half in New York; Health Ofi ia ls  Say New 
Funds, Drugs May Drive Trend, WASH. POST, Jan. 25, 1997, at A1 (discussing the positive 
impact of the New York State ADAP, particularly in New York City). 
96 See Study Details Limited Reach of ADAPs Despite Funding Jump, MED. & HEALTH, 
July 14, 1997, available in 1997 WL 8689240 (noting that Arkansas, Nevada, Oregon, and 
South Dakota do not cover the approved inhibitors). 
96 See AIDS Lobbies Push for Expanded Care Coverage, AIDS ALERT, Jan. 1, 1998, at 6 
(noting the legislatively imposed dichotomy between AIDS and HIV). 
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money, to fund AIDS treatment rather than AIDS prevention, will 
ultimately prove extremely short-sighted. 
E. Denial of Access Due to Noncompliance 
One of the most poignant ways in which AIDS patients both ex- 
perience and symbolize the problems of patients with chronic ill- 
nesses is in compliance. While compliance means different things 
in different disease contexts, it generally refers to the ability and 
willingness of a patient to adhere to the treatment plan developed 
by the physician, including refraining from medically injurious be- 
havior and taking prescription drugs at  intervals that will maxi- 
mize their efficacy. For an obese patient with high blood pressure 
and cardiovascular disease, compliance means quitting smoking, 
changing eating habits, taking medication to lower blood pressure, 
and learning to exercise in moderation. For a patient who is dia- 
betic, it means eating appropriate meals on a regular basis, moni- 
toring blood glucose levels regularly, and taking oral or injectable 
insulin at  prescribed levels. For an HIV-positive or AIDS patient, 
compliance requires adhering to a strictly-timed regimen of taking 
as many as twenty pills a day, some on an empty stomach and some 
after a meal, as well as meeting the requirements for good health in 
everyone: eating nutritious meals, getting a good night's sleep in a 
safe place, and refraining from use of alcohol and other drugs. The 
latter requirements may be difficult to meet for many HIV-positive 
and AIDS patients, who may be homeless, poor, and using drugs. 
With the advent of combination drug therapies, compliance for 
patients with HIV and AIDS has become particularly complex.97 
On the one hand, these new pharmaceutical interventions promise 
significant remission in disease symptoms for many individuals, 
allowing them to return to work and to their normal lives. On the 
other, preliminary data make clear that even occasional lapses in 
compliance may nullify the efficacy of these drugs in halting the on- 
slaught of AIDS, when patients develop a drug-resistant strain of 
the HIV virus.98 Even more troubling, if the noncompliant patient 
97 See generally Sontag & Richardson, supra note 1, at A1 (discussing the "minefield of 
ethical, legal rind public health concerns" and how strict compliance is necessary with combi- 
nation drug therapies or else the virus may become resistant to treatment). 
9s See DAVID A. MORTON 111, MEDICAL PROOF OF SOCW SECURITY DISABILITY 2.15 
(Supp. 1996) (stating that noncompliance by persons with tuberculosis has resulted in the 
development of drug-resistant strains of the disease and that poor compliance by persons 
with AIDS may have the same effect); see also Jennifer L. Rosato, The Ultimate Test of 
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transmits this new version of the virus to others, through sexual 
contact or intravenous drug use, the new virus can spread widely 
throughout the population. 
Thus, practitioners caring for an HIV or AIDS patient have com- 
peting obligations, to the patient and the community, in deciding 
whether to prescribe a regimen of combination therapies to a pa- 
tient whom they suspect may have compliance difficulties. First, 
can the patient's compliance be predicted? Studies of AIDS and 
other diseases suggest that physicians are poor predictors of com- 
pliance, and that it is important to disregard stereotypes based on 
race, gender, social class, or drug use.99 Second, in light of the ex- 
pense of combination therapies and the potential for the patient to 
develop drug-resistance, it is critical that the practitioner spend 
ample time discussing possible pitfalls with the patient and con- 
sider delaying, for a short while, the implementation of drug ther- 
apy, because the patient has only one chance to make it work.100 
Broader public health concerns are even more difficult to resolve. 
The lessons of dealing with non-compliant patients with active, 
drug-resistant tuberculosis (TB) may be useful, although they are 
not strictly parallel. With active TB, it is possible to mandate a 
short course (twice a week for two to four weeks) of directly ob- 
served therapy to ensure that a patient is taking the medication 
and thus eliminate the risk of transmission of active, drug-resistant 
TB.101 With AIDS and HIV, the requirement of combination ther- 
apy is expected to be indefinite, and the patient monitoring re- 
quired to ensure compliance around the clock impracticable. The 
incredible success of combination therapy itself may provide the 
necessary "carrot" to encourage compliance, as patients who feel 
healthier are much more likely to continue treatment. In this view, 
it would be beneficent parentalism at its worst to prejudge the 
likely outcome for a particular patient who could be given the op- 
- 
Autonomy: Should Minors Have a Right to Make Decisions Regarding Life Sustaining 
Treatment?, 49 RUTGERS L. REV. 1,61 n.265 (1996) (noting that drug resistant strains o f  HIV 
may result from poor compliance). 
99 See Clinicians Explore Ways To Ensure Compliance: More Counseling Needed, AIDS 
ALERT, Feb. 1,1997, available in  1997 W L  8961919 (suggesting that physicians should design 
a medication schedule tailored to a patient's lifestyle). 
100 See MORTON, supra note 98, 4 2.15 (stating that physicians should provide patients 
with suggestions for remembering medication regimens as well as maintain contact with the 
patient to monitor compliance); Sontag & Richardson, supra note 1, at A1 (noting the dilem- 
mas physicians face when deciding whether to treat patients with combination drugs). 
101 See Newark v. J.S., 652 A.2d 265, 269 (N.J. Super. Ct. 1993) (stating that non- 
compliance may lead to relapse and development of  a drug resistant strain of tuberculosis). 
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portunity to try protease inhibitors. Thus, all patients must be 
given a chance to benefit from the new therapies, as well as the 
support system necessary to make a chance worth taking. 
F. Denial of Access Because of Lack of Insurance: The Limitations 
of an Employment-Linked Health Care System 
The evolution of AIDS over the last fifteen years is a lens through 
which to examine the strengths and weaknesses of the American 
health care system. The most significant weakness is that for peo- 
ple under 65 health care coverage is tied closely to employment 
status.102 It is largely an historical accident that health insurance 
coverage became employment-based, due to World War I1 price con- 
trollers who determined to exempt employee benefits from wage 
and price controls.103 Today, as more Americans are aging out of 
the ranks of the employed, and many Americans are working part- 
time, or at  low wage jobs that do not provide health insurance bene- 
fits, the wisdom of this decision is being reexamined.104 In the case 
of people with HIV and AIDS, as with many other chronic diseases, 
most people try to work until they are too sick to continue, often 
seeking reasonable accommodation in employment tasks along the 
way. One of the most significant barriers to adequate health care is 
the trend of employers to self-insure for the health care needs of 
their employees rather than purchase insurance on their employees' 
behalf.105 Under ERISA, self-insured employee benefit plans are 
not subject to state laws whose purpose is to guarantee minimum 
access standards to workers and their dependents.106 Thus, em- 
ployers are free to impose disease specific caps on coverage, or re- 
102 In 1996,64% of Americans were covered by employmentbased health insurance. See 
FRONSTIN, supra note 28, at 3-4. 
10s See Dayna Bowen Matthew, Controlling the Reverse Agency Costs of Employment- 
Based Health Insurance: Of Markets, Courts, and a Regulatory Quagmire, 31 WAKE FOREST 
L. REV. 1037,1041-42 (1996). 
104 Indeed, President Clinton's proposal to expand Medicare to include people aged 55-64 
reflects this new economic reality. See Robert Pear, Clinton Plan To Widen Medicare Can't 
Pay for Itself; Experts Say, N.Y. TIMES, Jan. 20, 1998, at A1 (critiquing a plan that would al- 
low persons under 65 to buy full Medicare coverage). 
105 See Thomas E. Bartnun, Fear, Discrimination and Dying in the Workplace: AlDS and 
the Capping of Employees' Health Insurance Benefits, 82 KY. L.J. 249, 253-54 (1994) 
(explaining that such a tactic allows employers to cut administrative costs while circum- 
venting state insurance laws). 
106 See 29 U.S.C. 55 1001-1461 (1994). 
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quire greater co-payments for certain illnesses than others.lo7 The 
question of whether an insurer's decision to discriminate against 
individuals with certain types of illnesses in its underwriting vio- 
lates the ADA is a complex issue that has received little attention 
from the courts until recently. In Parker v. Metropolitan Life In- 
surance Co.,l08 the Sixth Circuit Court of Appeals held, over a 
strong dissent, that the distinction between mental and physical 
illness in the length of coverage provided by an employer purchased 
disability policy did not violate Title I11 of the ADA.109 The Court 
found that the ADA was not violated because Title I11 (governing 
places of public accommodation) applies only to physical structures, 
and thus the ADA does not govern insurance policies which were 
purchased by the employer for the benefit of its employees, as op- 
posed to an individual entering into an insurance company's of- 
fice.110 The Court further reasoned that providing disability policies 
with different benefits depending on the nature of the disability did 
not run afoul of the ADA because the ADA was denied to remedy 
discrimination between the disabled and the non-disabled, and not 
discrimination between individuals with different disabilities.111 
Thus, it would appear under the Parker court's reasoning, that a 
self-insured employer could distinguish among diseases, insuring 
HIV and AIDS, in the amount of health care coverage it provided. 
Another court has held that where an employer purchased health 
insurance from a company that refused to offer aG insurance to an 
employee with AIDS, the ADA was violated.112 It-is as yet unclear 
what the impact of HIPAA will be on the question of permissible 
discrimination on the basis of HIV positive or AIDS status, as the 
avowed purpose of HIPAA was to ensure that people should not be 
denied insurance coverage due to a preexisting condition.113 How- 
107 See McGann v. H & H Music Co., 946 F.2d 401 (5th Cir. 1991) (affirming summary 
judgment for an employer who changed health plans to reduce maximumbenefits for em- 
ployees suffering from AIDS from $1 million to $5000, holding that such actions are not pro- 
hibited by ERISA). 
108 121 F.3d 1006 (6th Cir. 1997). 
109 See id. at 1015 (stating "[tlhe disparity in benefits provided in the policy at  issue is also 
not prohibited by the ADA because the ADA does not mandate equality between individuals 
with different disabiliti'esn). 
110 See id. .at 1011 n.3. 
111 See id. at  1015. 
112 See Anderson v. Gus Mayer Boston Store, 924 F. Supp. 763, 781 (E.D. Tex. 1996) 
(holding that choosing an insurer that would never cover an employee because of his disabil- 
ity denied the employee equal access to insurance, thus discriminating against him). 
11s See Eric Mills Holmes, Solving the ZnsurancelGenetic Fair1 Unfair Discrimination Di- 
lemma in Light of the Human Genome Project, 85 KY. L.J. 503, 657-58 (1997) (stating that a 
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ever, in Parker the court rejected this argument. It reasoned first 
that the enactment of the Mental Health Parity Act of 1996 as an 
amendment to HIPAA reflected congressional understanding that 
the ADA did not apply to insurance policies.114 second, it concluded 
that the limitation of the Mental Health Parity Act to health insur- 
ance (as opposed to disability) policies demonstrated a collective 
congressional belief that there was not a strong need to provide 
parity between mental and physical disabilities in this realm of in- 
surance coverage or in the realm of disability insurance coverage. 115 
Once employees become too disabled to work, many will try to ex- 
ercise their options under the Consolidated Omnibus Budget Rec- 
onciliation Act of 1985 (COBRA)116 to continue their work-based in- 
surance coverage for the eighteen month maximum period, and 
then seek coverage under the employer's disability insurance plan. 
Ultimately, persons with HIV/AIDS and other chronic diseases are 
likely to seek government assistance through Medicaid, spending 
themselves into poverty in order to qualify. However, current 
Medicaid eligibility criteria limit coverage to persons who have full- 
blown AIDS, excluding persons who are HIV-positive.117 Many 
AIDS advocates have questioned the wisdom of these criteria ar- 
guing that the need for health care services is equally great a t  the 
moment of initial HIV diagnosis, because many prophylactic strate- 
gies are most successful then, and will thus decrease the costs of 
AIDS treatment overall.ll8 
AIDS has come of age in the 1990s. It has undergone a dramatic 
metamorphosis from a little understood, often unspeakable, and 
rare disease, affecting a relatively small number of people who were 
already socially stigmatized. AIDS is now a mainstream disease, 
affecting people across the nation, from all segments of society, 
"goal of the Act is to improve portability and continuity of an employee's group health insur- 
ance coverage under ERISA when an employee . . . with a pre-existing condition changes em- 
ployers"). 
"4 See Parker, 121 F.3d at 1018. 
116 See id. 
116 29 U.S.C. $ 1161 (1994). 
117 See Isbell, supra note 24, at 32 (noting that most HIV-infected adults obtain Medicaid 
through supplemental security income, requiring a physician's diagnosis of full-blown AIDS 
to meet disability regulations). 
118 See id. at 33 (discussing a study estimating that 60% of people infected with HIV could 
benefit from early intewention). 
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even as its sufferers are primarily the poor and persons of color, 
who are most likely to have difficulty in gaining access to quality 
health care. 
Because of the recent dramatic advances in the clinical treatment 
of AIDS, and the potential of forestalling many cases from advanc- 
ing from HIV to AIDS, people with AIDS are now living with a 
chronic disease. AIDS, like all chronic diseases, needs medical 
management that is continuing, aggressive, expensive, and com- 
plex. The problems faced by persons with HIV and AIDS are the 
same as those confronted by other Americans with chronic diseases, 
despite the media attention that AIDS has received which has often 
made AIDS appear sui generis, a disease unto itself. As we near 
the close of the twentieth century, it is worth reflecting on the les- 
sons we have learned from the AIDS epidemic, to consider how we 
might transform the American health care system to serve the 
needs of all its citizens-the healthy, the chronically ill, and the 
acutely ill and injured. 
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